๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Experience With Low-Dose Valganciclovir Prophylaxis in Adult Liver Transplant Recipients

โœ Scribed by R. Dupuis; M. Harris; K. Gillis; D. Gerber; J. Fair; R. Watson; T. Koslowski; K. Andreoni

Book ID
116933845
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
80 KB
Volume
39
Category
Article
ISSN
0041-1345

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Valganciclovir for cytomegalovirus proph
Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients
โœ Jeong M. Park; Kathleen D. Lake; Robert J. Fontana ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 48 KB

We thank Jain et al. for their interest and correspondence regarding our recently published study. 1 The authors note that the incidence of cytomegalovirus (CMV) disease in our retrospective study was much lower than that reported by others. As acknowledged in our article, we did not use routine sur

Efficacy and safety of low-dose valganci
Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients
โœ Jeong M. Park; Kathleen D. Lake; Juan D. Arenas; Robert J. Fontana ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 85 KB ๐Ÿ‘ 1 views

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a d